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Introduction
Recent studies have shown that microarray analysis of
tumors generate molecular phenotypes that can be used
to classify tumors into subgroups that are not evident by
traditional histopathological methods, to improve diagno-
sis, and to predict outcomes of disease [1–6]. In a recent
study, van ’t Veer et al. [7] reported, among other impor-
tant conclusions, that expression profiles of sporadic
primary breast tumors could be used to predict disease
recurrence better than currently available clinical and
histopathological prognostic factors (i.e. tumor grade,
tumor size, angioinvasion, age, and estrogen receptor
[ER]-α). Those investigators identified a set of 231 genes,
from which they extracted 70 that were used to predict
recurrences within 5 years with an accuracy of 89% for a
test set of 20 tumors. However, our experience suggests
that, in breast cancer patient populations, predicting clini-
cal variables from gene expression data is complicated by
a common correlation between ER-α status and the clini-
cal parameters studied. ER-α status has been shown to
leave a remarkable imprint on the expression profile of a
tumor, and may have confounding effects on the clinical
factor studied [7–9]. Therefore, we believe that it is neces-
sary to be cautious when interpreting the results from the
study of van ’t Veer et al. and similar studies.
In the set of tumors analyzed by Van’t Veer et al. [7] there
is an evident correlation between clinical outcome for the
patients and ER-α status of the tumors. For that reason,
we investigated whether their results can be applied to a
data set from a different patient cohort in which there is no
correlation between ER-α status and prognosis.
Estrogen receptor-α α and gene expression in
breast cancer
ER-α status is by far the most obvious and noticeable
subdivision of breast tumors based on gene expression
profiles. This has become evident in several studies
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[4,7–9]. In a previous study [8] we used the gene expres-
sion profiles of 47 tumors and artificial neural networks to
generate a prediction model based on the 100 highest
ranked discriminator genes that could accurately predict
the ER-α status of 11 breast tumors from an independent
test set. Furthermore, we found that sets of genes much
further down our ranked list still carried substantial infor-
mation about ER-α status. Using a similar approach, West
et al. [9] also succeeded in predicting the ER-α status of a
set of breast tumors. In their study, van ’t Veer et al. [7]
also found that the main subdivision of tumors by unsuper-
vised clustering was into two groups based on ER-α
status. Indeed, there is considerable overlap between the
genes that discriminate ER-α status in their data and
those that were reported by us and by West et al. In addi-
tion, van’t Veer et al. also found that as many as 2460
genes (out of 24,479 included in their arrays) carried infor-
mation on ER-α status, confirming our finding that a large
number of genes expressed in breast tumors are associ-
ated with ER-α status.
Prediction of prognosis from gene expression
profiles
In the study by van ’t Veer et al. [7], disease recurrence
was better predicted using the expression signature of 70
identified genes as compared with currently available clini-
cal and histopathological prognostic factors (tumor grade,
tumor size, angioinvasion, age, and ER-α status). We
investigated the expression of approximately 7000 genes
in a patient cohort of 44 primary breast tumors (size
20–50 mm, from lymph node-negative patients all treated
with adjuvant tamoxifen). In contrast to the findings of
van ’t Veer et al., we could not predict relapse with statisti-
cal confidence. The tumors we studied were selected to
comprise four nearly equal sized groups: ER-α-positive or
ER-α-negative, each subdivided into good (no distant
metastases within a follow-up period of 5–11 years,
median 8.0 years) and poor (distant metastases within
6 years, median 2.6 years) prognosis groups (Fig. 1).
Using either artificial neural networks [5,8] or the signal-to-
noise statistic [1] and random permutation tests, we were
unable to develop a statistically reliable outcome classifier
in these data. This may suggest that, because ER-α-posi-
tive and ER-α-negative tumors have such distinct expres-
sion profiles, the molecular pathways that are
characteristic of the aggressive tumors within these two
groups may not overlap to a substantial degree. Hence, it
would probably be beneficial for those two groups to be
considered separately when predicting prognosis on the
basis of gene expression profiles. Unfortunately, such an
analysis could not be performed satisfactorily in this data
set because the number of tumors in the ER-α subgroups
was too low. Additionally, it should be noted that the effect
of ER-α status on outcome might be even more pro-
nounced in this data set because the patients received
endocrine treatment after primary surgical resection.
Furthermore, we investigated whether the outcome pre-
dictor gene set generated by van ’t Veer et al. [7] could be
applied to our patient cohort. We found that none of the
outcome predictor genes identified by those investigators,
which were also represented in our array data (58 out of
231), was a significant outcome discriminator (α < 0.01;
as performed in Allander et al. [10]) in our material. In
order to verify that the 58 genes still had significant pre-
dictive power in the dataset reported by van ’t Veer et al.,
we used their ‘leave one out’ supervised classification
method in their data and found that these 58 genes still
discriminated the two prognostic classes (odds ratio [OR]
= 5.7, 95% confidence interval [CI] 2.1–15; P = 0.0007
[Fisher’s exact test]), whereas no discrimination was seen
in our data (OR = 1.9, 95% CI 0.5–6; P = 0.4). We used
multidimensional scaling analysis to illustrate these results
(Fig. 2).
Intriguingly, for the training set of 58 sporadic tumor
samples that van ’t Veer et al. [7] analyzed, their super-
vised ER-α predictor gene set also had predictive power
for outcome (OR = 3.7, 95% CI 1.3–11; P = 0.02),
perhaps owing to the predominance (80%) of ER-α-posi-
tive tumors in the good prognosis group (Fig. 3). Likewise,
in their independent test set, all of the tumors with a good
prognosis were ER-α-positive except one (86%; Fig. 4). In
addition, 71% of the 231 prognostic genes identified by
van ’t Veer et al. were also listed by them as ER-α status
reporter genes, confirming an overlap between the predic-
tors of prognosis and ER-α status. It is important to note,
however, that they were able to achieve better prognostic
predictions using the 231 selected genes (OR = 15, 95%
CI 4–56; P = 0.000004) than with the ER-α predictor
gene set. Nevertheless, we believe that the correlation
between prognosis and ER-α status in samples reported
by van ’t Veer et al. (Figs 3 and 4) might have led to the
selection of a prognostic gene set that may not be broadly
applicable to other breast tumor cohorts in which no cor-
relation between ER-α status and prognosis exists.
Figure 1
The distribution of clinical characteristics in our 44 sporadic breast
tumors. Estrogen receptor-α status is denoted as ER+ and ER–.
Clinical outcome for the patients is represented by M+ (distant
recurrences within 6 years) and M– (no recurrences within a follow-up
period of at least 5 years). Microarray data were generated as
described by Gruvberger et al. [8].
 M+  M– 
ER+  12  8       20
ER–  12       12      24
  24       20 25
Conclusion
Most breast cancer gene expression studies to date have
examined limited sample numbers and tend not to have
sufficient power to allow analysis within standard clinico-
pathologically defined subsets. Moreover, the majority of
breast cancer patients today receive some form of postop-
erative treatment (radiation, endocrine and/or chemother-
apy) that influences the clinical course and significance of
prognostic factors. In general, there are risks inherent in
the development of a prognostic classifier from a sample
set comprised of patients who are heterogeneous for clini-
copathological variables of known prognostic significance.
Although the resulting predictive classifier may accurately
describe the sample set used for its development, that
result may merely reflect the influence of known prognos-
tic variables on gene expression, and it may fail when
applied to an independent test set containing patients
who are indistinguishable on the basis of all standard clini-
cal and pathological markers, but who still differ in terms
of outcome. Although it is still of great importance to gain
an understanding of which patterns of gene expression
are linked to known variables such as ER-α status, studies
should be designed to reveal rather than obscure these
links, and to uncover any potential gene expression pat-
terns that predict outcome within uniform groups. If
microarray based prognostic tools are to become widely
used in the clinical setting, then additional studies must be
conducted that seek and independently validate prognos-
tic information in larger sample sets, which are carefully
selected and matched with respect to known prognostic
variables, such as ER-α status and therapy.
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Figure 2
Multidimensional scaling (MDS) clustering of gene expression data
from breast tumors using 58 out of 231 genes from the outcome
predictor gene set identified by van ’t Veer et al. [7] that were also
included in our array analysis. These genes retain their predictive value
in those data but not in our independent patient sample. (a) Fifty-eight
primary breast tumors (training set) from the study by van’t Veer et al.
and (b) 44 from our array study are plotted. Tumors with a poor
prognosis (distant recurrences within 6 years) are colored blue and
tumors with a good prognosis (no recurrences within a follow-up
period of 5–14 years) are orange. MDS displays the position of each
tumor sample in a three-dimensional euclidean space, with the
distance between the samples reflecting their approximate degree of
correlation [11].
Figure 3
The distribution of clinical characteristics of the 78 sporadic breast
tumors used in the training/validation set in the study by van ’t Veer et
al. [7]. Estrogen receptor-α status is denoted as ER+ and ER–.
Clinical outcome for the patients is represented by M+ (distant
recurrences within 5 years) and M– (no recurrences within a follow-up
period of at least 5 years).
 M+  M– 
ER+  21  35     56
ER–  13  9       22
 34  44 
Figure 4
The distribution of clinical characteristics of the 19 sporadic breast
tumors used as an independent test set in the study by van’t Veer et al.
[7]. Estrogen receptor-α status is denoted as ER+ and ER–. Clinical
outcome for the patients is represented by M+ (distant recurrences
within 5 years) and M– (no recurrences within a follow-up period of at
least 5 years).
 M+  M– 
ER+   6  6      12
ER–   6  1       7
 12  7 26
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